Metronidazole Vaginal Gel
NDC Package 45802-139-70
Package Information
Metronidazole Vaginal (metronidazole) gel is metronidazole Vaginal Gel is indicated in the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, Corynebacterium vaginitis, or anaerobic vaginosis).NOTE: For purposes of this indication, a clinical diagnosis of bacterial vaginosis is usually defined by the presence of a homogeneous vaginal discharge that (a) has a pH of greater than 4.5, (b) emits a "fishy" amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. This formulation utilizes a gel delivery system. Marketed by Padagis Israel Pharmaceuticals Ltd, this product is identified by NDC 45802-139 and is authorized under FDA application ANDA211786.
Identification & Billing
- RxCUI: 142046 - metroNIDAZOLE 0.75 % Vaginal Gel
- RxCUI: 142046 - metronidazole 0.0075 MG/MG Vaginal Gel
- RxCUI: 142046 - metronidazole 0.75 % Vaginal Gel
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 45802 - Padagis Israel Pharmaceuticals Ltd
- 45802-139 - Metronidazole Vaginal
- 45802-139-70 - 1 TUBE in 1 CARTON / 70 g in 1 TUBE
- 45802-139 - Metronidazole Vaginal
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 45802-139-70 identifies a specific commercial package of 1 tube in 1 carton / 70 g in 1 tube of Metronidazole Vaginal, a human prescription drug labeled by Padagis Israel Pharmaceuticals Ltd. This gel is formulated for vaginal use and contains metronidazole as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Padagis Israel Pharmaceuticals Ltd on July 08, 2019. The current certification is valid through December 31, 2026.
How is this Padagis Israel Pharmaceuticals Ltd product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 45802013970. Quantities are measured in per "gm or gram", products billed per gram are products measured by weight.. There are 70 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.